BR112014010594A2 - terapia genética para neuropatia diabética empregando um isoforma do hgf - Google Patents

terapia genética para neuropatia diabética empregando um isoforma do hgf

Info

Publication number
BR112014010594A2
BR112014010594A2 BR112014010594A BR112014010594A BR112014010594A2 BR 112014010594 A2 BR112014010594 A2 BR 112014010594A2 BR 112014010594 A BR112014010594 A BR 112014010594A BR 112014010594 A BR112014010594 A BR 112014010594A BR 112014010594 A2 BR112014010594 A2 BR 112014010594A2
Authority
BR
Brazil
Prior art keywords
diabetic neuropathy
isoforms
hgf
present
employing
Prior art date
Application number
BR112014010594A
Other languages
English (en)
Inventor
Gyun Jeong Jae
Mook Kim Jong
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of BR112014010594A2 publication Critical patent/BR112014010594A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

abstract the present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of hgf or a polynucleotide encoding the isoforms. the present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of hgf. according to the present invention, it is possible to very effectively treat diabetic neuropathy. ___________________________________________________________ tradução resumo patente de invenção: "terapia genética para neuropatia diabética empregando um isoforma do hgf". a presente invenção se refere a uma composição farmacêutica para a prevenção ou o tratamento de neuropatia diabética, em que a composição farmacêutica compreende, como ingredientes ativos, diferentes tipos de isoformas do hgf ou um polinucleotídeo codificando as isoformas. a presente invenção é a primeira invenção demonstrando que a neuropatia diabética pode ser evitada e tratada empregando empregando diferentes tipos de isoformas do hgf. de acordo com a presente invenção, é possível muito eficientemente tratar a neuropatia diabética.
BR112014010594A 2011-11-03 2012-03-27 terapia genética para neuropatia diabética empregando um isoforma do hgf BR112014010594A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110113786 2011-11-03
PCT/KR2012/002224 WO2013065913A1 (ko) 2011-11-03 2012-03-27 Ｈｇｆ 이형체를 이용한 당뇨병성 신경병증의 유전자 치료

Publications (1)

Publication Number Publication Date
BR112014010594A2 true BR112014010594A2 (pt) 2017-05-02

Family

ID=48192237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010594A BR112014010594A2 (pt) 2011-11-03 2012-03-27 terapia genética para neuropatia diabética empregando um isoforma do hgf

Country Status (7)

Country Link
US (4) US9963493B2 (pt)
KR (2) KR20140089363A (pt)
AU (1) AU2012333408B2 (pt)
BR (1) BR112014010594A2 (pt)
CA (1) CA2853918C (pt)
MX (1) MX2014005318A (pt)
WO (1) WO2013065913A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761852T3 (es) 2015-01-21 2020-05-21 Centre Nat Rech Scient Proteínas agonistas del receptor MET
CA3079506A1 (en) * 2017-10-18 2019-04-25 Helixmith Co., Ltd. Treatment of neuropathy with dna construct expressing hgf isoforms with reduced interference from gabapentinoids
WO2019132624A1 (ko) 2017-12-29 2019-07-04 주식회사 헬릭스미스 하이브리드 hgf 유전자가 도입된 aav(아데노-연관 바이러스) 벡터
KR20200144576A (ko) * 2018-05-17 2020-12-29 주식회사 헬릭스미스 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료
JP7380670B2 (ja) * 2018-07-17 2023-11-15 ヘリックスミス カンパニー， リミテッド Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療
JP7413629B2 (ja) 2018-07-17 2024-01-16 ヘリックスミス カンパニー， リミテッド Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
WO2022211454A1 (ko) * 2021-03-29 2022-10-06 주식회사 헬릭스미스 샤르코-마리-투스병 예방 또는 치료용 약제학적 조성물
KR20230129933A (ko) 2022-03-02 2023-09-11 에이치앤비지노믹스 주식회사 다유전자 및 임상 정보 융합 기반의 당뇨병성 신증 발병 위험도 예측 방법 및 장치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036103A1 (en) * 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
WO2007142651A1 (en) * 2006-06-09 2007-12-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods and compositions for the treatment of neuropathy
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor

Also Published As

Publication number Publication date
KR101817665B1 (ko) 2018-01-16
US20200354420A1 (en) 2020-11-12
AU2012333408B2 (en) 2016-05-26
CA2853918C (en) 2020-12-29
US20180222955A1 (en) 2018-08-09
US20140296142A1 (en) 2014-10-02
US9963493B2 (en) 2018-05-08
WO2013065913A1 (ko) 2013-05-10
KR20140089363A (ko) 2014-07-14
US20190241632A1 (en) 2019-08-08
US10759841B2 (en) 2020-09-01
AU2012333408A1 (en) 2014-05-29
CA2853918A1 (en) 2013-05-10
MX2014005318A (es) 2015-01-14
KR20170024614A (ko) 2017-03-07

Similar Documents

Publication Publication Date Title
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112016021648A2 (pt) novos compostos
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
BR112012030029A2 (pt) beta-lactamases modificadas e métodos e usos relacionados a elas
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112016011472A2 (pt) tienopirimidinas como inibidores de mknk1 e mknk2
BR112014011641A2 (pt) composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
BR112015018549A8 (pt) métodos de tratamento de deficiência de ferro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.